2026
article
OpenAlex
C. Michael Gibson, Philippe Gabríel Steg, M. Cecilia Bahit, Rasha Al-Lamee et autres
BACKGROUND: Patients are at increased risk for recurrent ischemic events after an acute coronary syndrome event. Milvexian, an oral factor XIa inhibitor, may reduce the risk of major adverse clinical events with minimal bleeding risk. METHODS: In this phase 3, randomized, placebo-controlled …
us, fr, ar, gb, ca, jp, br, cn, rs, in, il, kr, nl, pl, de, hu, ro, cz, es, it, Afrique du Sud, sk, tw, pt, my, tr, mx, be, nz, mk, ch, gr, au, vn, ph, dk, at, lt, lv, sg, cl
(code pays fourni par la source)
2026
article
OpenAlex
Ahmad Masri, Martin S. Maron, Ankit Bhatia, Maria Luisa Peña-Peña et autres
BACKGROUND: Nonobstructive hypertrophic cardiomyopathy (HCM) is a common condition that is associated with substantial morbidity and no proven medical therapy. Whether treatment with aficamten, a cardiac myosin inhibitor, can benefit patients with this condition is unknown. METHODS: In this phase 3, multinational, …
us, es, br, il, gb, ar, cn, nl, it, dk, de, hu
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Evan L. O’Keefe, Brett Wesley Sperry, Philip G. Jones, James Henry O’Keefe et autres
BACKGROUND: Cardiac stress testing is a cornerstone of risk stratification and management in patients with chronic coronary disease, yet the consistency and accuracy of its interpretation remain poorly defined. This analysis evaluated variation in the interpretation of myocardial ischemia between enrollment sites …
us
(code pays fourni par la source)